Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease
Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease
Biological treatments (BT) are commonly prescribed to treat chronic inflammatory diseases in
 children. Paradoxical reactions during treatment with a biological agent can be defined as
 the appearance or exacerbation of a pathological condition that usually responds to this
 class of drug while treating a patient for another condition. Limited data are available in
 children treated by BT on cutaneous paradoxical reactions, or any other cutaneous adverse
 events occurring during treatment. On the contrary, dermatologists tend to see and manage
 increasing numbers of cutaneous adverse events, including paradoxical reactions. The aim of
 this project is to describe the incidence of cutaneous adverse events, including cutaneous
 paradoxical reactions, occurring in the pediatric population, during a treatment by BT given
 for a chronic inflammatory disease.
Inclusion Criteria:

 -  Children under 18 years old

 -  Children treated by biotherapy among : Adalimumab, Golimumab, Infliximab, Ustekinumab,
 Etanercept, Tocilizumab, Canakinumab, Anakinra, Abatacept.

 -  Children treated for a chronic inflammatory disease (rheumatologic,
 gastro-enterologic, dermatologic and ophthalmologic)

 -  Children treated in the CHU of Amiens

 -  Parental consent signed

 Exclusion Criteria:

 -  Age > 18 ans